[HTML][HTML] The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies

R Bai, Y Li, L Jian, Y Yang, L Zhao, M Wei - Molecular Cancer, 2022 - Springer
Given that hypoxia is a persistent physiological feature of many different solid tumors and a
key driver for cancer malignancy, it is thought to be a major target in cancer treatment …

[HTML][HTML] Porphyrin/chlorin derivatives as promising molecules for therapy of colorectal cancer

F Dandash, DY Leger, M Diab-Assaf, V Sol, B Liagre - Molecules, 2021 - mdpi.com
Colorectal cancer (CRC) is a leading cause of cancer-related death. The demand for new
therapeutic approaches has increased attention paid toward therapies with high targeting …

[HTML][HTML] Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3

YM Chung, PP Khan, H Wang, WB Tsai… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Stimulating antitumor immunity by blocking programmed death-1 (PD-1) or its
ligand (programmed death-ligand 1 (PD-L1) is a promising antitumor therapy. However …

Hypoxia-inducible factor-1α induces multidrug resistance protein in colon cancer

Y Lv, S Zhao, J Han, L Zheng, Z Yang… - OncoTargets and …, 2015 - Taylor & Francis
Multidrug resistance is the major cause of chemotherapy failure in many solid tumors,
including colon cancer. Hypoxic environment is a feature for all solid tumors and is important …

Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor

R Kumar, EJ Kim, J Han, H Lee, WS Shin, HM Kim… - Biomaterials, 2016 - Elsevier
Hypoxia, a distinguished feature of various solid tumors, has been considered as a key
marker for tumor progression. Inadequate vasculature and high interstitial pressures result in …

[HTML][HTML] Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis

S Kawai, N Takeshima, Y Hayasaka, A Notsu… - BMC cancer, 2021 - Springer
Background Irinotecan (IRI) and oxaliplatin (Ox) are standard therapeutic agents of the first-
line treatments for metastatic colorectal cancer (mCRC). Previous meta-analyses of …

Engineering nanomedicines to inhibit hypoxia-inducible Factor-1 for cancer therapy

X Zhang, C He, G Xiang - Cancer Letters, 2022 - Elsevier
Abstract Hypoxia-inducible factor-1 (HIF-1), an essential promoter of tumor progression, has
attracted increasing attention as a therapeutic target. In addition to hypoxic cellular …

Tumor microenvironment-responsive nanoparticle delivery of chemotherapy for enhanced selective cellular uptake and transportation within tumor

WC Huang, SH Chen, WH Chiang, CW Huang… - …, 2016 - ACS Publications
A novel drug delivery strategy featured with enhanced uptake of nanoparticles (NPs) by
targeted tumor cells and subsequent intratumoral cellular hitchhiking of chemotherapy to …

Triggering reactive oxygen species field effect transistor based on HIF‐1α signaling for enhanced chemodynamic therapy

Z Zhao, J Yan, K Ling, R Shi, R Lv… - Advanced Functional …, 2021 - Wiley Online Library
A hypoxic tumor microenvironment (TME) makes tumors resistant to various therapies
including chemotherapies, radiotherapies, and photodynamic therapies. Here, a new …

Sub-100 nm, long tumor retention SN-38-loaded photonic micelles for tri-modal cancer therapy

X Yang, X Xue, Y Luo, T Lin, H Zhang, D Lac… - Journal of Controlled …, 2017 - Elsevier
The tumor penetration and accumulation of nanoparticle-based drug delivery systems are
highly dependent on the particle size. Nanomedicines in the sub-100 nm range have been …